- Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trialXu, B.; Yan, M.; Ma, F.; Li, W.; Ouyang, Q.; Tong, Z.; Teng, Y.; Wang, S.; Wang, Y.; Geng, C.; Luo, T.; Zhong, J.; Zhang, Q.; Liu, Q.; Zeng, X.; Sun, T.; Mo, Q.; Dong, F.; Wu, S.; Zhu, X.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.被引 11
- A comparative analysis of secondary data from the ToGA and EVIDENCE studies on the effectiveness of trastuzumab plus chemotherapy in Asian patients with HER2+metastatic gastric cancerShen, L.; Wu, T.; Chen, P.; Qin, S.; Ji, J.; Wu, Y.; Chen, Y.; Chen, Y.; Wang, J.; Wu, Y.23rd ESMO World Congress on Gastrointestinal Cance, ELECTR NETWORK, 2021-06-30 To 2021.
- The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in Chinese patients (pts) with HER2-positive early breast cancer (EBC): Primary analysis of the phase III, randomised FDChina studyShao, Z.; Huang, T.; Fan, Z.; Wang, Y.; Yan, X.; Yang, H.; Wang, S.; Pang, D.; Li, H.; Wang, H.; Geng, C.; Huang, L.; Siddiqui, A.; Wang, B.; Xie, B.; Sun, G.; Restuccia, E.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
期刊论文
Trastuzumab beyond progression in HER2‐positive metastatic breast cancer
3阅读
